Potential role of BRCA1 protein expression as a prognostic tissue biomarker in breast carcinoma: an immunohistochemical and clinicopathologic study from South India
, 2, 1, 1, 3, 4
Abstract
Introduction. BRCA1 dysfunction is a hallmark of both hereditary and sporadic breast cancer. BRCA1 protein expression can be lost by germline mutation, somatic mutation or promoter hypermethylation. This study aimed to explore BRCA1 dysfunction in breast cancer patients by immunohistochemistry and to study its association with prognostic factors.
Material and methods. BRCA1 protein expression was assessed by immunohistochemistry on formalin fixed paraffin embedded tissue blocks of 110 invasive breast carcinoma patients. Furthermore, the clinical findings and tumor features associated with BRCA1 dysfunction were characterized.
Results. Reduced BRCA1 immunoreactivity was observed in 19% of breast cancer cases. Although these patients presented with aggressive tumor characteristics, statistical significance was observed only with presence of lymphovascular emboli (p < 0.05). These results suggest that loss of BRCA1 protein expression is associated with an aggressive phenotype of breast carcinoma.
Conclusions. Immunohistochemistry for BRCA1 protein expression in tumor tissues may provide a less expensive screening tool to identify BRCA1 dysfunction due to genetic or epigenetic alterations.
Keywords: breast cancerBRCA1biomarkerimmunohistochemistryPARP inhibitor
References
- Lima ZS, Ghadamzadeh M, Arashloo FT, et al. Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms. J Hematol Oncol. 2019; 12(1): 38.
- Takaoka M, Miki Y. BRCA1 gene: function and deficiency. Int J Clin Oncol. 2018; 23(1): 36–44.
- Stoppa-Lyonnet D. The biological effects and clinical implications of BRCA mutations: where do we go from here? Eur J Hum Genet. 2016; 24 Suppl 1: S3–S9.
- Miyamoto K, Fukutomi T, Asada K, et al. Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers. Jpn J Clin Oncol. 2002; 32(3): 79–84.
- Domagala P, Hybiak J, Cybulski C, et al. BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness. Int J Cancer. 2017; 140(7): 1545–1550.
- Kim D, Jung W, Koo JaS. The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes. J Korean Med Sci. 2011; 26(3): 352–359.
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–249.
- Breast and cervical cancers on the rise in Kerala, says Health Ministry- The New Indian Express. https://www.newindianexpress.com/states/kerala/2019/dec/21/breast-and-cervical-cancers-on-the-rise-in-kerala-says-health-ministry-2078944.html.
- Malvia S, Bagadi SA, Dubey US, et al. Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol. 2017; 13(4): 289–295.
- Secord AA, Berchuck A, Cerami E. Cohort of Ovarian Carcinomas. 2014; 37(1): 138–146.
- Urbina-Jara LK, Rojas-Martinez A, Martinez-Ledesma E, et al. Landscape of Germline Mutations in DNA Repair Genes for Breast Cancer in Latin America: Opportunities for PARP-Like Inhibitors and Immunotherapy. Genes (Basel). 2019; 10(10).
- Dutil J, Teer JK, Golubeva V, et al. Germline variants in cancer genes in high-risk non-BRCA patients from Puerto Rico. Sci Rep. 2019; 9(1): 17769.
- Keung MY, Wu Y, Vadgama JV. PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. J Clin Med. 2019; 8(4).
- Hussein IA, Ahmed STh, Hameedi AD, et al. Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study. Asian Pac J Cancer Prev. 2020; 21(4): 1025–1029.
- Dehuri P, Kanungo S. Utility of evaluation of P53 and BRCA1 in invasive breast cancers: An immunohistochemical study. Indian J Pathol Oncol. 2019; 6(1): 123–127.
- Verma D, Agarwal K, Tudu SK. Expression of breast cancer type 1 and its relation with expression of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2/neu in breast carcinoma on trucut biopsy specimens. Indian J Pathol Microbiol. 2018; 61(1): 31–38.
- Vaz FH, Machado PM, Brandão RD, et al. Familial breast/ovarian cancer and BRCA1/2 genetic screening: the role of immunohistochemistry as an additional method in the selection of patients. J Histochem Cytochem. 2007; 55(11): 1105–1113.
- Hedau S, Batra M, Singh UR, et al. Expression of BRCA1 and BRCA2 proteins and their correlation with clinical staging in breast cancer. J Cancer Res Ther. 2015; 11(1): 158–163.
- Lee WY. Frequent loss of BRCA1 nuclear expression in young women with breast cancer: an immunohistochemical study from an area of low incidence but early onset. Appl Immunohistochem Mol Morphol. 2002; 10(4): 310–315.
- Rakha EA, El-Sheikh SE, Kandil MA, et al. Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol. 2008; 39(6): 857–865.
- Yoshikawa K, Honda K, Inamoto T, et al. Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases. Clin Cancer Res. 1999; 5(6): 1249–1261.
- Meisel JL, Hyman DM, Garg K, et al. The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer. Ann Oncol. 2014; 25(12): 2372–2378.
- Garg K, Levine DA, Olvera N, et al. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. Am J Surg Pathol. 2013; 37(1): 138–146.
- Manchana T, Tantbirojn P, Pohthipornthawat N. immunohistochemistry for screening of mutation in epithelial ovarian cancer patients. Gynecol Oncol Rep. 2020; 33: 100582.